References
- Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431.
- Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–1444.
- Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193–201.
- Elman MJ, Ayala A, Bressler NM, et al. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122:375–381.
- Boyer DS, Nguyen QD, Brown DM, et al. Outcomes with as-needed Ranibizumab after initial monthly therapy: long-term outcomes of the phase III RIDE and RISE trials. Ophthalmology. 2015;122:2504–2513.
- Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015;122:2044–2052.
- Heier JS, Clark WL, Boyer DS, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion. Ophthalmology. 2014;121:1414–1420.
- Ogura Y, Roider J, Korobelnik J-F, et al. for the GALILEO study group. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol. 2014;158:1032–1038.
- Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions. Long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119:802–809.
- Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292–2299.
- Gillies MC, Campain A, Barthelmes D, et al. on behalf of the fight retinal blindness study group. Long-term outcomes of treatment of neovascular age-related macular degeneration. Data from an observational study. Ophthalmology. 2015;122(9):1837–1845.
- Peden MC, Suñer IJ, Hammer ME, et al. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration. Ophthalmology. 2015;122:803–808.
- Tano Y, Ohji M, EXTEND-I Study Group. Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration. Acta Ophthalmol. 2011;89:208–217.
- Lalwani GA, Rosenfeld PJ, Fung AE, et al. Variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148:43–58.
- Refillable ranibizumab reservoir for neovascular age-related macular degeneration [cited 2015 Oct 14]. Available from: http://retinatoday.com/2014/08/long-acting-anti-vegf-delivery
- The CATT Research Group, Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–1908.
- Birch DB, Weleber RG, Duncan JL, et al. Ciliary neurotrophic factor retinitis pigmentosa study groups. Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa. Am J Ophthalmol. 2013;156:283–292.
- Maclachlan T, Lukason M, Collins M, et al. Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. Mol Ther. 2011;19(2):326–334.
- Boyer DS A phase 2b study of Fovista, a platelet derived growth factor (PDGF) inhibitor in combination with a vascular endothelial growth factor (VEGF) inhibitor for neovascular age-related macular degeneration (AMD). ARVO 2013 Annual Meeting; 2013 May 5–9; Seattle, WA.
- Nguyen TT, Conbercept GR. (KH-902) for the treatment of neovascular age-related macular degeneration. Expert Rev Clin Pharmacol. 2015;8(5):541–548.
- Andrade GC, Dias JR, Maia A, et al. Intravitreal injections of ziv-aflibercept for diabetic macular edema. Retina. 2016 Mar 16. [Epub ahead of print].